

Balaxi Pharmaceuticals Limited

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No C/1, G Block, BKC
Bandra (E), Mumbai-400051

5th September, 2022

Stock Code: BALAXI

Sub: Outcome of the Board Meeting

Dear Sir/Madam,

With reference to the above subject, we wish to inform you that the Board of Directors at their meeting held on 5th September, 2022, subject to the approval of shareholders, considered and approved the following business:

1. Preferential Issue of 10,75,500 Warrants, each Warrant convertible into one Equity Share at an issue price of ₹ 451/- (Face value of ₹ 10 and premium of ₹ 441) upon exercising the Warrant.
2. Preferential issue of 24,500 Equity Shares at an issue price of ₹ 451/- (Face value of ₹ 10 and premium of ₹ 441)
3. Draft Notice of Extraordinary General Meeting of the shareholders of the Company scheduled to be held on **Tuesday, 27th September, 2022** through video conferencing or any other audio-visual means.

Further, the details pursuant to Regulation 30(2) of the Listing Regulations read with Para A of Annexure I and circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015 issued by Securities and Exchange Board of India ("SEBI") is enclosed herewith as an **Annexure A**.

The Board Meeting commenced at 11:40 AM and concluded at 1:50 PM.

The above information is available at the website of the Company at www.balaxipharma.in

This is for your information and record.

Thanking You

Yours Faithfully,
For Balaxi Pharmaceuticals Limited


Chinta Shalini
Company Secretary



Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balax.in | Website: www.balaxipharma.in

Balaxi Pharmaceuticals Limited

Annexure A

Details regarding the preferential issue which a listed entity needs to disclose as per the SEBI Circular dated September 09, 2015:

Particulars	Details
Type of securities proposed to be issued	1. Warrants convertible to Equity shares 2. Equity Shares
Type of issuance	Preferential Issue in accordance with Chapter V of the SEBI (ICDR) Regulations and other applicable laws
Total number of securities proposed to be issued or the total amount for which the securities will be issued	1. Preferential Issue of 10,75,500 Warrants convertible into Equity Shares 2. Preferential issue of 24,500 Equity Shares
Details of Investors:	

S. No.	Name of the Allottee	Number of Equity Shares/ Convertible Warrants
1.	Rajasthan Global Securities Private Limited	319000
2.	Kunal Bhakta	200000
3.	Faisal Zubair Hawa	110000
4.	Sachin Shetty	50000
5.	Ajit Kumar	25000
6.	Ketan Kirtikumar Vakharia	25000
7.	Gryphon Ventures LLP	25000
8.	Faisal Siddiqui	25000
9.	Glance Finance Ltd	25000
10.	Sheela Kothari	25000
11.	Anubhav Goyal	21000
12.	Ramchandran Subramaniam Swaminathan	20000
13.	Akshay Garg	20000
14.	Daizam Aggarwal	20000
15.	Aviraj Fincap LLP	20000
16.	Mohamed Aamer Mohamed Afzal Mithaiwala	12500
17.	Kamal Ladiwala	11000
18.	Meenakshi Agarwal	11000
19.	Sharad Narayanlal Sarda	10000
20.	Ruchira Goyal	10000

Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Balaxi Pharmaceuticals Limited

21.	Saurabh Dixit	10000
22.	Mangina Srinivas Rao	10000
23.	Deborshi Chaki	9000
24.	Ankur Gupta	6000
25.	Nishit Paleja	6000
26.	Archerchem Healthcare Private Limited	6000
27.	Kapil Katyal	6000
28.	Prateek Bansal	6000
29.	Jignesh S Kamani	5500
30.	Ashish S Kamani	5500
31.	Jiten Shah	5500
32.	Ray Capital	5000
33.	Pushpa Sarda	5000
34.	Prateek Ashok Sanghanian	5000
35.	Vinod Kela	5000
36.	Alka S Shah	5000
37.	Kirit Hirachand Sanghavi	5000
38.	Monica Sethia	5000
39.	Shailesh Jentilal Shah (HUF)	3000
40.	Sunny Purohit	2000

<p>Post allotment of securities - outcome of the subscription,</p> <p>issue price / allotted price (in case of convertibles),</p> <p>number of investors</p>	<ol style="list-style-type: none"> 1. Preferential Issue of 10,75,500 Warrants, each Warrant convertible into one Equity Share at an issue price of ₹ 451/- (Face value of ₹ 10 and premium of ₹ 441) upon exercising the Warrant, aggregating to ₹ 48,50,50,500 2. Preferential issue of 24,500 Equity Shares at an issue price of ₹ 451/- (Face value of ₹ 10 and premium of ₹ 441) aggregating to ₹ 1,10,49,500 <p>Total number of investors: 40</p>
<p>In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument</p>	<p>The Warrants shall be convertible into equal number of Equity Shares within a maximum tenure of 18 months from the date of allotment of Warrants.</p> <p>In case the Warrants are not exercised within the maximum tenure, the amount paid on the warrants shall get lapsed.</p>

Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in